Unresectable Melanoma Active Not Recruiting Phase 2 Trials for DB09035 (Nivolumab)

IndicationStatusPhase
DBCOND0047213 (Unresectable Melanoma)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01927419Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic MelanomaTreatment